(Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health ...

Shares of Gilead Sciences Inc. GILD rose 1.60% to $107.62 Thursday, on what proved to be an all-around great trading session ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to ...

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

A new building of condominiums — including three affordable units — has been proposed for Brighton Center. Biotech's Future - ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

A new drug that gives almost complete protection against the virus was to be administered across Africa this year. Now, much ...

The high court found that members of a task force that determines what preventive drugs must be covered can be removed at ...